Hubei Biocause Pharmaceutical Co., Ltd.

Simbol: 000627.SZ

SHZ

2.3

CNY

Tržna cena danes

  • -19.6629

    Razmerje P/E

  • 0.1626

    Razmerje PEG

  • 11.27B

    Kapaciteta MRK

  • 0.05%

    Donos DIV

Hubei Biocause Pharmaceutical Co., Ltd. (000627-SZ) Finančni izkazi

Na grafu so prikazane privzete številke v dinamiki za Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ). Prihodki podjetja prikazujejo povprečje NaN M, ki je NaN % gowth. Povprečni bruto dobiček za celotno obdobje je NaN M, ki je NaN %. Povprečno razmerje bruto dobička je NaN %. Rast čistega dobička za lanskoletno poslovanje podjetja je NaN %, kar je enako NaN % % v povprečju v celotni zgodovini podjetja.,

Bilanca stanja

Če pogledamo fiskalno pot podjetja Hubei Biocause Pharmaceutical Co., Ltd., opazimo povprečno rast sredstev. Zanimivo je, da ta stopnja znaša , kar odraža tako visoke kot tudi padce podjetja. Pri primerjavi četrtletja s četrtletjem se ta številka prilagodi na . Pogled nazaj v preteklo leto razkrije skupno spremembo sredstev v višini NaN. Vrednost za delničarje, kot jo prikazuje celotni lastniški kapital, je ovrednotena z vrednostjo NaN v valuti poročanja. Letna sprememba tega vidika je NaN%.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993

balance-sheet.row.cash-and-short-term-investments

02995228391.826157.8
30248.8
15203.5
18317.5
15336.9
10953.2
61.6
58.9
124.3
152.8
74.1
72.9
95.1
306.7
111.3
73.5
26.9
16.8
55.5
73.7
247
104.9
74.6
96
104.9
113.5
13.9
13.9
13.6

balance-sheet.row.short-term-investments

01798.42082.52907.5
3391.6
2211.8
62842.7
4164.8
50767.4
418.6
0
0
0
0
0
0
16.1
3.2
1.3
0
0
0
1.4
0
0
0
0
12
0
13.5
13.5
13.5

balance-sheet.row.net-receivables

00-28453.617772.1
15069.6
10639.8
45548.8
9204.3
7697.9
83.7
140.8
188.6
339.1
391
277
295.6
231
198.2
318.7
428
407.2
455.9
280.7
296.1
28.7
8.7
8
4.1
5.6
3.4
0.2
26

balance-sheet.row.inventory

04131.91050410224.5
10716.2
3671.6
3820.5
569.4
438.5
136.1
140.4
133.9
134.4
150.2
194.2
273.9
259.2
200.4
156.1
135
128.6
125.8
129.8
90.7
70.6
75.6
66.7
16.1
30
18.4
5.3
1.4

balance-sheet.row.other-current-assets

0045535.3-3796
-4291.5
-3729.8
-17868.2
2283.9
645.2
57.7
53.8
-8.1
-98.7
-45.5
-33.6
-29.1
-26.9
0.1
-93.8
-146.6
-130.9
-169.3
0
-105.7
171.7
92.1
73.9
23.9
18.1
23.2
19
-12.8

balance-sheet.row.total-current-assets

050665.955977.650358.4
51743.1
25785
49818.6
27394.5
19734.9
339.2
394
438.7
527.6
569.9
510.5
635.5
770
510
454.5
443.3
421.7
467.9
484.2
528.1
375.9
251.1
244.7
149
167.2
58.9
38.3
28.2

balance-sheet.row.property-plant-equipment-net

01290.6844.1830.3
580.4
567.2
770.9
698.9
587.4
334.7
454.2
619.2
601.7
448.9
527
798.5
612.4
374.3
354.7
336.6
343.3
338.4
322.2
262.9
355.1
376.4
274.9
159.7
111.5
63
32.9
26.5

balance-sheet.row.goodwill

06192.56192.26192.2
6192.2
6186.3
6186.3
6186.3
6186.3
0
0
0
0
0
1.8
1.8
1.8
1.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0283.2299.3269.7
190
109.4
213.4
519.9
549.1
490.4
503.9
363.5
374.7
382.8
410.6
363.6
316.5
261.9
257.6
179.6
186.8
189.1
184.4
123.5
105
109.3
16.4
16.8
16.3
10.8
3.8
3.9

balance-sheet.row.goodwill-and-intangible-assets

06475.76491.66461.9
6382.2
6295.7
6399.7
6706.2
6735.4
490.4
503.9
363.5
374.7
382.8
412.3
365.4
318.3
263.7
257.6
179.6
186.8
189.1
184.4
123.5
105
109.3
16.4
16.8
16.3
10.8
3.8
3.9

balance-sheet.row.long-term-investments

0133897.1129743.213020.4
12217.8
12396.1
12983.8
15056.2
8280.1
742
716.8
689.8
543.4
463.3
517.5
330.1
260.4
172.5
100.1
127
127.3
94
100.6
74.4
43.9
22.5
139.1
12
0
13.5
13.5
13.5

balance-sheet.row.tax-assets

026542280.31010.3
976.2
944.2
1189.4
39.5
69.8
69.3
30.5
45.7
17.3
18.7
8.9
9.1
7.6
4.7
-2.7
-127
-127.3
-94
-2.7
0
1.8
1.9
2.3
-12
0
-13.5
-13.5
-13.5

balance-sheet.row.other-non-current-assets

0106952.593262192222.6
167502.9
159285.8
107091.6
90521.3
82469.2
433.6
9.1
0
0
0
0
17.2
10.9
-0.7
3.2
128.4
129.5
95.6
1.7
0.2
4.6
9.4
5
44.3
35.9
1.7
3.1
1.4

balance-sheet.row.total-non-current-assets

0251270232621.1213545.5
187659.6
179488.9
128435.4
113022.2
98141.8
2070.1
1714.5
1718.3
1537.1
1313.7
1465.8
1520.3
1209.6
814.6
712.9
644.6
659.6
623.1
606.2
461
510.4
519.5
437.8
220.8
163.8
75.5
39.8
31.8

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

0301935.9288598.7263904
239402.6
205273.9
178254
140416.7
117876.7
2409.2
2108.5
2157
2064.7
1883.6
1976.3
2155.7
1979.5
1324.5
1167.4
1087.9
1081.3
1091
1090.4
989.1
886.3
770.7
682.5
369.8
331
134.4
78.2
60.1

balance-sheet.row.account-payables

0949206.993.5
35
156.5
83.5
106.1
82.8
74.4
112.8
208.7
84.8
62.6
34.8
37.5
45
67.9
119.6
45.7
51
25.7
26.8
18.6
51.6
29.5
40.1
19
12.5
7.5
3.1
0

balance-sheet.row.short-term-debt

018248.121189.69425.8
4583.8
6179.8
4640
7732.3
1414
303.5
428.9
484.6
327.8
253.2
142.8
274.8
192.7
279.4
231.9
252.4
251.4
284.4
249.4
134.5
154.4
96.4
54.9
7.7
14.9
8.1
3.3
6

balance-sheet.row.tax-payables

078.585.1142.5
65.4
223.8
338.4
19.2
53.3
2.1
3.7
-43.3
-48.5
-9.7
0.6
6.9
2.8
29.3
11.2
3.6
2.4
6.6
9.7
32
26.4
15.4
6.2
6.6
15.1
8.8
10.5
2.2

balance-sheet.row.long-term-debt-total

07170.86877.96203.6
2760.3
-69.4
110.5
40.5
360
42
0
0
23
123
123
225
160
30
30
0
0
0
0
0
9
14
14
58.4
56.8
24.4
2.7
5.8

Deferred Revenue Non Current

0179576.7241.8154781.7
147076.1
69.4
10.9
15.3
16
17.6
19.4
0
0
0
0
0
-160
-30
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

0463347.4258.5
52
69.4
21424.5
8957.1
2072
8.3
8.8
14.5
12.6
5.9
13.1
20.5
11.8
17.6
21.7
23.7
22.7
19.3
16.8
8.2
12.8
5.3
4.9
0.8
6.4
1.5
0.8
6.9

balance-sheet.row.total-non-current-liabilities

0243840.1229010213369.4
196798.4
162486.6
125753.1
103441.9
93669.4
198.5
41.3
15.8
34.8
134.5
134.5
225
160.2
30
30
0
0
0
0
0
9
16.2
15.2
58.4
56.8
24.4
2.7
5.8

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

071.689.6111.2
69.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

0268302.2253995.8226429.3
204814.7
170920.5
152239.5
113711.8
97479.2
625.5
618.8
720.7
527.4
469.5
374.2
581.3
466.8
458.5
443.7
356.7
357.4
372.2
322.4
226.1
291.8
199
189.5
176.6
130.9
82
34.3
18.8

balance-sheet.row.preferred-stock

001085.90
763.7
595.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

04940.64940.64940.6
4940.6
4940.6
4940.6
4940.6
4259.2
1353.6
1353.6
1353.6
1353.6
1353.6
1353.6
676.8
676.8
594.8
594.8
594.8
594.8
594.8
594.8
517.2
278.9
232.4
129.1
103.2
103.2
40.5
40.5
40.5

balance-sheet.row.retained-earnings

053106508.56327.4
5909.4
5829
4247.5
3142.4
1922.7
184.6
-37
-171.9
-70.8
-82.7
19
104.6
58.6
106.1
13.1
-31.5
-37.4
-41.7
6.4
27.8
73.4
59.9
36.2
12
32.9
3.4
0
0.8

balance-sheet.row.accumulated-other-comprehensive-income-loss

00-1085.9236.6
-763.7
-595.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

010339.49962.811048.6
10284.9
10453.5
9804
11254
7619.9
201.5
132.4
214.1
214.7
105.3
172.4
736.8
726.2
113.6
99.1
94.7
93.5
92.8
92.8
143.6
175.4
215.1
312.4
77.9
64
8.5
3.3
0

balance-sheet.row.total-stockholders-equity

020590.12141222553.3
21134.9
21223.1
18992.1
19337
13801.8
1739.7
1449
1395.8
1497.5
1376.2
1545
1518.2
1461.6
814.5
707
658
650.9
645.9
694
688.7
527.7
507.4
477.7
193.2
200.1
52.4
43.9
41.3

balance-sheet.row.total-liabilities-and-stockholders-equity

0301935.9288598.7263904
239402.6
205273.9
178254
140416.7
117876.7
2409.2
2108.5
2157
2064.7
1883.6
1976.3
2155.7
1979.5
1324.5
1167.4
1087.9
1081.3
1091
1090.4
989.1
886.3
770.7
682.5
369.8
331
134.4
78.2
60.1

balance-sheet.row.minority-interest

013043.71319114921.3
13453
13130.4
7022.5
7367.8
6595.7
44
40.7
40.4
39.9
37.9
57
56.3
51.2
51.6
16.7
73.2
73
72.9
74.1
74.3
66.8
64.2
15.3
0
0
0
0
0

balance-sheet.row.total-equity

033633.834602.937474.7
34587.9
34353.5
26014.5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0135695.6131825.7116261.7
119224.9
120538.2
75826.6
61072.9
59047.4
1160.6
716.8
689.8
543.4
463.3
517.5
330.1
244.3
169.3
98.7
127
127.3
94
99.2
74.4
43.9
22.5
139.1
24
0
27
27
27

balance-sheet.row.total-debt

025418.928067.59425.8
4583.8
6179.8
4640
7732.3
1414
303.5
428.9
484.6
327.8
253.2
142.8
274.8
192.7
279.4
231.9
252.4
251.4
284.4
249.4
134.5
154.4
96.4
54.9
7.7
14.9
8.1
3.3
6

balance-sheet.row.net-debt

0-2734.71758.2-13824.5
-22273.3
-6811.9
-13677.5
-3439.9
-9539.2
241.9
370
360.3
175
179.1
69.9
179.7
-97.9
171.4
159.7
225.5
234.6
228.9
177.1
-112.5
49.6
21.7
-41.1
-85.2
-98.7
7.7
2.9
5.9

Izkaz denarnih tokov

V zadnjem obdobju se je v finančnem okolju Hubei Biocause Pharmaceutical Co., Ltd. opazno spremenil prosti denarni tok, ki se je spremenil v NaN. Podjetje je nedavno povečalo svoj osnovni kapital z izdajo NaN, kar kaže na razliko NaN v primerjavi s prejšnjim letom. Družba je pri naložbenju porabila neto denarna sredstva v višini NaN v valuti poročanja. To je premik za NaN v primerjavi s prejšnjim letom. V istem obdobju je družba zabeležila NaN, NaN in NaN, ki so pomembne za razumevanje naložbenih in odplačilnih strategij podjetja. Družba je pri financiranju porabila NaN, pri čemer je razlika v primerjavi z letom prej znašala NaN. Poleg tega je podjetje namenilo NaN za izplačilo dividend svojim delničarjem. Hkrati je izvajalo tudi druge finančne manevre, imenovane NaN, ki so prav tako pomembno vplivali na denarni tok v tem obdobju. Te sestavine skupaj tvorijo celovito sliko finančnega stanja podjetja in strateškega pristopa k upravljanju denarnih tokov.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998

cash-flows.row.net-income

0510.6880.21117.9
2918.6
2377.3
2678.3
3108.8
250.5
84.1
-100.4
13.8
-107.2
29.1
55.3
17.1
101.6
53.1
8.1
4.9
-49
7.8
46.7
40.3
35.4
30.5

cash-flows.row.depreciation-and-amortization

0147.3133.963.7
79.2
1123.9
122.9
139.3
64.8
73.5
68.8
52.4
62.9
66.5
52.3
40.5
42
35.6
37.6
35.9
34.2
37.3
28.9
28.6
25.1
13.1

cash-flows.row.deferred-income-tax

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

016073.111933.530709.3
35361
-26789.8
5245.9
-6232.5
23.9
-78.9
116.7
78
51.7
149.3
-122.8
-96.1
27.3
51.8
-13.7
15
-22.3
-131.2
-41.5
-83.5
-23.6
-52.1

cash-flows.row.account-receivables

01642.4-609.1-279.5
1548.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-279.6471.1-188.3
177.6
120.5
-130.9
-302.4
1.7
-6.5
0.5
15.8
12.3
79.7
-14.7
-58.7
-44.4
-21
-6.4
-1.8
4
-37.2
-20.1
4.9
8.9
-29

cash-flows.row.account-payables

0-1642.4609.1279.5
-1548.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

016352.611462.530897.6
35183.5
-26910.3
5376.7
-5930.1
22.2
-72.4
116.2
62.2
39.5
69.6
-108.1
-37.3
71.6
72.9
-7.3
16.8
-26.3
-94
-21.4
-88.4
-32.5
-23.1

cash-flows.row.other-non-cash-items

0-9206.7-8775.1-10469.8
-9759.2
38269.9
-7615.5
642
-385.9
-200
45.4
-50.4
59.5
-20.2
-5.3
24.9
-52.3
-12.4
16.7
0.3
11.2
16.5
3.2
10
10
3.4

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-135.1-287.1-308.4
-717.1
-274.7
-778.9
-3678.3
-40.8
-185.5
-143.8
-128.5
-149.4
-93.1
-261.7
-361.7
-64.8
-130.1
-24.5
-25.5
-21.5
-146.1
-31.5
-6.3
-99.2
-10.8

cash-flows.row.acquisitions-net

0171.8-3440.5
258.8
334.3
1.4
3.5
3.2
103.1
162.9
131
44.3
0
263.4
361.8
65.9
130.1
0
28.3
21.8
146.9
0.2
10.7
0
10.8

cash-flows.row.purchases-of-investments

0-97626.8-109755-71494.6
-123082.8
-77372.7
-139091.6
-115403.5
-6.2
-230
-146.7
-60
-40
-120.1
-40
-189
-60
-55.6
-0.8
-39
-165.8
-184.7
-24.8
-20.2
0
-31.5

cash-flows.row.sales-maturities-of-investments

084126.194717.767783.5
88942.6
68035
129051.5
104526.6
182.1
464.4
89
130
170
0
17.8
92.7
43.2
26.7
0
15.6
175.7
129.6
1.1
12.2
29.9
12

cash-flows.row.other-investing-activites

0-1996.2-62.2-222.2
-445.9
102.8
-47.8
17138.3
7.1
5.3
-143.8
-128.5
-149.4
207.6
-261.7
-361.7
-64.8
-130.1
0
-25.5
-21.5
-146.1
62
-6.3
0.5
-10.8

cash-flows.row.net-cash-used-for-investing-activites

0-15615-15384.8-7682.2
-35044.3
-9175.3
-10865.4
2586.6
145.4
157.2
-182.4
-56
-124.4
-5.6
-282.2
-458
-80.4
-159
-25.3
-46.2
-11.3
-200.6
7
-9.9
-68.8
-30.3

cash-flows.row.debt-repayment

0-11763.8-7701.9-854.1
-102.8
-288
-790
-447.5
-464.9
-573.5
-463.3
-294.8
-223.3
-594.8
-279.7
-413.2
-231.9
-255.8
-240.6
-235.4
-329.9
-345.9
-178.9
-59.8
-67.9
-17.2

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-699.4-381.3-634
-242.1
-311.6
-148
-117.1
-24.5
-30.6
-30.4
-28.7
-21.6
-37.3
-20
-52.4
-17.8
-12.3
-14.3
-15.5
-15
-16.1
-22.7
-15.1
-6.2
-58.7

cash-flows.row.other-financing-activites

02354115703.91660.6
1470.2
1940.4
11597.1
11190.3
407
515.3
484.6
364.4
303.7
390.8
406.8
1119.6
247.4
344.2
241.6
202.4
364.9
457.5
299.4
119.6
74.8
114.5

cash-flows.row.net-cash-used-provided-by-financing-activities

011077.87620.6172.6
1125.3
1340.8
10659.2
10625.7
-82.4
-88.8
-9.1
40.9
58.8
-241.3
107.2
654.1
-2.3
76.2
-13.3
-48.6
20
95.5
97.8
44.7
0.6
38.6

cash-flows.row.effect-of-forex-changes-on-cash

072-15.2-33.9
-1.4
1.6
-2.1
3.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
0

cash-flows.row.net-change-in-cash

03059-3606.913877.6
-5320.8
7148.4
223.2
10873.7
16.2
-52.8
-61.1
78.7
1.3
-22.2
-195.5
182.6
35.8
45.3
10
-38.7
-16.8
-174.7
142.2
30.2
-21.4
3.1

cash-flows.row.cash-at-end-of-period

026309.323250.326857.1
12979.5
18300.4
11152
10928.8
55.1
38.9
91.8
152.8
74.1
72.9
95.1
290.6
108
72.2
26.9
16.8
55.5
72.3
247
104.9
74.6
96

cash-flows.row.cash-at-beginning-of-period

023250.326857.112979.5
18300.4
11152
10928.8
55.1
38.9
91.8
152.8
74.1
72.9
95.1
290.6
108
72.2
26.9
16.8
55.5
72.3
247
104.9
74.6
96
92.9

cash-flows.row.operating-cash-flow

07524.24172.621421.1
28599.6
14981.3
431.6
-2342.3
-46.7
-121.3
130.5
93.8
66.9
224.6
-20.5
-13.5
118.6
128.2
48.7
56.1
-25.9
-69.6
37.3
-4.6
46.9
-5.2

cash-flows.row.capital-expenditure

0-135.1-287.1-308.4
-717.1
-274.7
-778.9
-3678.3
-40.8
-185.5
-143.8
-128.5
-149.4
-93.1
-261.7
-361.7
-64.8
-130.1
-24.5
-25.5
-21.5
-146.1
-31.5
-6.3
-99.2
-10.8

cash-flows.row.free-cash-flow

07389.13885.521112.7
27882.5
14706.7
-347.4
-6020.6
-87.5
-306.8
-13.3
-34.7
-82.4
131.5
-282.2
-375.2
53.8
-1.9
24.1
30.5
-47.4
-215.8
5.8
-10.9
-52.3
-16

Vrstica izkaza poslovnega izida

Prihodki Hubei Biocause Pharmaceutical Co., Ltd. so se v primerjavi s prejšnjim obdobjem spremenili za NaN%. Bruto dobiček podjetja 000627.SZ znaša NaN. Odhodki iz poslovanja podjetja so NaN in so se v primerjavi s prejšnjim letom spremenili za NaN%. Odhodki za amortizacijo znašajo NaN, kar je NaN% sprememba glede na zadnje obračunsko obdobje. Stroški poslovanja so sporočeni v višini NaN, ki kaže NaN% spremembo glede na preteklo leto. Stroški prodaje in trženja znašajo NaN, kar pomeni NaN% spremembo v primerjavi s preteklim letom. EBITDA na podlagi zadnjih podatkov znaša NaN in predstavlja NaN% rast v primerjavi s preteklim letom. Prihodki iz poslovanja so NaN, ki kažejo NaN% spremembo v primerjavi s preteklim letom. Sprememba čistih prihodkov je NaN%. Čisti prihodki v zadnjem letu so znašali NaN.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

income-statement-row.row.total-revenue

049725.849615.749583.2
43576
50192.1
30950.8
53405.6
16995.5
541.1
806.4
968
779.7
1133.8
1261.2
964.6
909.3
835.8
560.8
518.7
463
422.7
348.6
356
322
255.9
192.3
237.5
143.7
83.3

income-statement-row.row.cost-of-revenue

09829.68458.67311.6
3225.1
8172.6
2866.9
4036.6
1788.5
518
829.8
977.5
753.2
1111.8
1185.8
866.2
835.1
726.1
475.6
451.1
410.6
380.8
268.7
261.2
240.2
193
155.3
176.4
98.2
53.9

income-statement-row.row.gross-profit

039896.241157.142271.6
40350.8
42019.5
28083.9
49368.9
15207
23.1
-23.4
-9.6
26.5
22
75.3
98.4
74.2
109.7
85.1
67.7
52.5
41.8
79.9
94.9
81.8
62.8
37
61.2
45.6
29.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0-48509.69825.59896.8
36146.5
30062.1
-24280.3
-23688.3
-6190.4
3.1
8.3
13.2
1.5
0.3
9.8
6
5
6
10.3
4.7
9.5
1.5
2.6
8.3
7.3
20.6
11.9
5.6
6.6
2

income-statement-row.row.operating-expenses

0-48509.610159.510437.9
36774.7
30668.5
2614.7
26761
6911.4
79.6
70.9
73.6
63.9
80.2
67.9
52.8
59
55.4
45.9
49.3
50.8
83.4
57
45
36.6
36.2
13
10
10.3
6.8

income-statement-row.row.cost-and-expenses

0-51566.718618.117749.5
39999.8
38841.1
5481.6
30797.6
8699.9
597.6
900.7
1051.1
817.1
1192
1253.7
919
894.1
781.4
521.5
500.4
461.3
464.2
325.6
306.1
276.7
229.2
168.3
186.3
108.5
60.7

income-statement-row.row.interest-income

0000
0
0
0
16.1
0
2.3
2.6
1.5
2.2
3.7
1.8
2.7
14.7
4.2
3.9
0.5
3.2
0.2
1.7
5.2
1.5
0
0
0
0
0

income-statement-row.row.interest-expense

0031200.6423.8
170.5
101.3
0
0
0
24.5
30.6
30.4
28.7
21.6
25.8
23.3
32.1
21
16.1
14.3
13.9
15.5
10.7
8.5
8.3
-0.4
-0.6
0.3
1.4
0.3

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-1868-30964.1-32573.9
-2432.1
-8419.3
-18306.3
-4428.3
-1585.5
390.9
203.2
-45.4
52.4
-58.5
23.6
13.6
-7.9
58.1
13.2
-14.4
0.5
-9.5
-9.1
-0.2
-3.1
6.1
12.8
6.6
10.1
6.2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0-48509.69825.59896.8
36146.5
30062.1
-24280.3
-23688.3
-6190.4
3.1
8.3
13.2
1.5
0.3
9.8
6
5
6
10.3
4.7
9.5
1.5
2.6
8.3
7.3
20.6
11.9
5.6
6.6
2

income-statement-row.row.total-operating-expenses

0-1868-30964.1-32573.9
-2432.1
-8419.3
-18306.3
-4428.3
-1585.5
390.9
203.2
-45.4
52.4
-58.5
23.6
13.6
-7.9
58.1
13.2
-14.4
0.5
-9.5
-9.1
-0.2
-3.1
6.1
12.8
6.6
10.1
6.2

income-statement-row.row.interest-expense

0031200.6423.8
170.5
101.3
0
0
0
24.5
30.6
30.4
28.7
21.6
25.8
23.3
32.1
21
16.1
14.3
13.9
15.5
10.7
8.5
8.3
-0.4
-0.6
0.3
1.4
0.3

income-statement-row.row.depreciation-and-amortization

01840.9147.3133.9
63.7
79.2
1123.9
122.9
139.3
64.8
73.5
68.8
52.4
62.9
66.5
52.3
40.5
42
35.6
37.6
35.9
34.2
37.3
28.9
28.6
25.1
13.1
-11.9
-13.4
-8.3

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

01216.331188.832917
3881.5
12052.8
2653.6
2727.4
3424.8
332.2
101.1
-141.1
14.9
-113.7
22.2
53.2
2.3
106.4
53.1
8.2
-1.7
-45.1
15.8
57.5
48.3
41.8
30.7
63.1
48.6
30.8

income-statement-row.row.income-before-tax

0-1868224.8343.1
1449.5
3633.4
2636.4
2724.3
3432.6
334.4
109
-128.6
15
-116.7
31.1
59.2
7.3
112.4
57.9
8.4
5
-47.3
16.2
57.7
48.9
47.6
39.7
63.3
50.3
30.8

income-statement-row.row.income-tax-expense

0-1216.3-285.8-537.1
331.6
714.9
259.1
46
323.7
83.9
24.8
-28.1
1.2
-9.5
2
3.9
-0.1
20.5
4.8
0.3
0.1
1.7
8.3
11
8.5
12.2
9.2
8.5
13.4
8

income-statement-row.row.net-income

0-651.8510.6880.2
1117.9
2918.6
1326.5
1326.2
1778.7
247.3
83.8
-101
11.8
-101.7
28.3
55.8
-23.8
89.7
48.4
7.1
5.1
-48.1
5.3
37.2
34.2
31.3
30.2
54.8
36.9
22.8

Pogosto zastavljeno vprašanje

Kaj je Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) skupna sredstva?

Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) skupna sredstva so 301935930342.000.

Kakšen je letni prihodek podjetja?

Letni prihodki so N/A.

Kolikšna je stopnja dobička podjetja?

Dobiček podjetja je 0.698.

Kakšen je prosti denarni tok podjetja?

Prosti denarni tok je -2.454.

Kolikšna je neto stopnja dobička podjetja?

Čista stopnja dobička je -0.007.

Kolikšni so skupni prihodki podjetja?

Celotni prihodki so 0.006.

Kaj je Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) čisti dobiček (čisti dobiček)?

Čisti dobiček (čisti prihodek) je -651784800.000.

Kolikšen je skupni dolg podjetja?

Skupni dolg je 25418877126.000.

Kolikšni so stroški poslovanja?

Stroški poslovanja so -48509569700.000.

Kolikšno je število denarnih sredstev podjetja?

Denarna sredstva podjetja so 0.000.